» Articles » PMID: 24704833

Targeting Colon Cancer Cell NF-κB Promotes an Anti-tumour M1-like Macrophage Phenotype and Inhibits Peritoneal Metastasis

Overview
Journal Oncogene
Date 2014 Apr 8
PMID 24704833
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

In a model of peritoneal metastasis in immune-competent mice, we show that nuclear factor (NF)-κB inhibition in CT26 colon cancer cells prevents metastasis. NF-κB inhibition, by stable overexpression of IκB-α super-repressor, induced differential polarization of co-cultured macrophages to an M1-like anti-tumour phenotype in vitro. NF-κB-deficient cancer cell-conditioned media (CT26/IκB-α SR) induced interleukin (IL)-12 and nitric oxide (NO) synthase (inducible NO synthase (iNOS)) expression in macrophages. Control cell (CT26/EV) conditioned media induced high levels of IL-10 and arginase in macrophages. In vivo, this effect translated to reduction in metastasis in mice injected with CT26/ IκB-α SR cells and was positively associated with increased CD8(+)CD44(+)CD62L(-) and CD4(+)CD44(+)CD62L(-) effector T cells. Furthermore, inhibition of NF-κB activity induced high levels of NO in infiltrating immune cells and decreases in matrix metalloproteinase-9 expression, simultaneous with increases in tissue inhibitor of metalloproteinases 1 and 2 within tumours. CT26/IκB-α SR tumours displayed increased pro-inflammatory gene expression, low levels of angiogenesis and extensive intratumoral apoptosis, consistent with the presence of an anti-tumour macrophage phenotype. Macrophage depletion reduced tumour size in CT26/EV-injected animals and increased tumour size in CT26/IκB-α SR cells compared with untreated tumours. Our data demonstrate, for the first time, that an important implication of targeting tumour cell NF-κB is skewing of macrophage polarization to an anti-tumour phenotype. This knowledge offers novel therapeutic opportunities for anticancer treatment.

Citing Articles

NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.

Bahrami A, Khalaji A, Najafi M, Sadati S, Raisi A, Abolhassani A Eur J Med Res. 2024; 29(1):610.

PMID: 39702532 PMC: 11658081. DOI: 10.1186/s40001-024-02168-w.


NF-κB signaling pathway in tumor microenvironment.

Cao Y, Yi Y, Han C, Shi B Front Immunol. 2024; 15:1476030.

PMID: 39493763 PMC: 11530992. DOI: 10.3389/fimmu.2024.1476030.


NF-κB downstream miR-1262 disturbs colon cancer cell malignant behaviors by targeting FGFR1.

Zhang W, Huang Z, Xiao Z, Wang H, Liao Q, Deng Z Acta Biochim Biophys Sin (Shanghai). 2023; 55(11):1819-1832.

PMID: 37867436 PMC: 10686795. DOI: 10.3724/abbs.2023235.


Cannabinoids Transmogrify Cancer Metabolic Phenotype via Epigenetic Reprogramming and a Novel CBD Biased G Protein-Coupled Receptor Signaling Platform.

Bunsick D, Matsukubo J, Szewczuk M Cancers (Basel). 2023; 15(4).

PMID: 36831374 PMC: 9954791. DOI: 10.3390/cancers15041030.


Natural Plant Extract - Loganin: A Hypothesis for Psoriasis Treatment Through Inhibiting Oxidative Stress and Equilibrating Immunity via Regulation of Macrophage Polarization.

Chen X, Deng Q, Li X, Xian L, Xian D, Zhong J Clin Cosmet Investig Dermatol. 2023; 16:407-417.

PMID: 36817639 PMC: 9936880. DOI: 10.2147/CCID.S396173.


References
1.
Mueller M, Fusenig N . Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4(11):839-49. DOI: 10.1038/nrc1477. View

2.
Wang Y, He F, Feng F, Liu X, Dong G, Qin H . Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010; 70(12):4840-9. DOI: 10.1158/0008-5472.CAN-10-0269. View

3.
OGorman A, Colleran A, Ryan A, Mann J, Egan L . Regulation of NF-kappaB responses by epigenetic suppression of IkappaBalpha expression in HCT116 intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2010; 299(1):G96-G105. DOI: 10.1152/ajpgi.00460.2009. View

4.
Ridnour L, Windhausen A, Isenberg J, Yeung N, Thomas D, Vitek M . Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A. 2007; 104(43):16898-903. PMC: 2040425. DOI: 10.1073/pnas.0702761104. View

5.
Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M . M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009; 206(5):1089-102. PMC: 2715025. DOI: 10.1084/jem.20081605. View